Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalyn Pharma Inc. - common stock (NQ:AVLN)

30.29 -0.30 (-1.00%)
Delayed Quote Updated: 11:59 AM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Avalyn Pharma Inc. - common stock

News headline image
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Present at Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs 
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Company expects to report topline 12-month clinical results in the second half of 2027 
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in the Jefferies Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.